Merck Financial Statements From 2010 to 2022

MRK -  USA Stock  

USD 93.55  1.46  1.59%

Merck financial statements provide useful quarterly and yearly information to potential Merck Company investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Merck financial statements helps investors assess Merck's valuation, profitability, and current liquidity needs.
There are currently one hundred sixteen fundamental ratios for Merck that can be evaluated and compared over time across peers in the industry. Please compare all of Merck last-minute fundamentals against the fundamentals between 2010 and 2022 to make sure the company is sustainable this year.
Merck Market Capitalization is increasing as compared to previous years. The last year's value of Market Capitalization was reported at 193.59 Billion. The current Working Capital is estimated to increase to about 7.6 B, while Average Assets are projected to decrease to under 90.9 B.
  
Refresh
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck main balance sheet or income statement drivers, such as Direct Expenses of 18.3 B, Consolidated Income of 10.9 B or Cost of Revenue of 13.4 B, as well as many exotic indicators such as Interest Coverage of 10.94, Long Term Debt to Equity of 0.97 or Calculated Tax Rate of 28.54. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules. It can also supplement various Merck Technical models. Additionally, see the analysis of Merck Correlation against competitors.

Merck Revenues

43.73 Billion

Share

Merck Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets96.4 B105.7 B97.4 B
Decreasing
Slightly volatile
Cash and Equivalents8.3 B8.1 B9.8 B
Decreasing
Slightly volatile
Investments379.7 M370 M8.9 B
Decreasing
Slightly volatile
Investments Current714.9 M696.6 M2.7 B
Decreasing
Stable
Investments Non Current379.7 M370 M6.4 B
Decreasing
Slightly volatile
Property Plant and Equipment Net18.7 B19.3 B15.2 B
Increasing
Stable
Inventory5.5 BB5.7 B
Decreasing
Slightly volatile
Tax Assets5.4 B5.5 B4.7 B
Increasing
Slightly volatile
Trade and Non Trade Receivables9.1 B9.2 B7.5 B
Increasing
Stable
Trade and Non Trade Payables4.2 B4.6 BB
Increasing
Slightly volatile
Goodwill and Intangible Assets38.9 B44.2 B37.9 B
Decreasing
Slightly volatile
Total Liabilities67.8 B67.4 B56.2 B
Increasing
Slightly volatile
Shareholders Equity37 B38.2 B41 B
Decreasing
Slightly volatile
Accumulated Retained Earnings Deficit53.8 B53.7 B44.5 B
Increasing
Slightly volatile
Current Assets28.7 B30.3 B30.4 B
Decreasing
Slightly volatile
Assets Non Current67.7 B75.4 B67 B
Decreasing
Slightly volatile
Current Liabilities24.2 B23.9 B20.2 B
Increasing
Slightly volatile
Liabilities Non Current43.6 B43.6 B36.1 B
Increasing
Slightly volatile
Tax Liabilities5.1 B4.7 BB
Decreasing
Slightly volatile
Total Debt32 B33.1 B25.1 B
Increasing
Slightly volatile
Debt Current3.2 B2.4 B3.3 B
Increasing
Stable
Debt Non Current28.7 B30.7 B21.8 B
Increasing
Slightly volatile
Shareholders Equity USD37 B38.2 B41 B
Decreasing
Slightly volatile
Cash and Equivalents USD8.3 B8.1 B9.8 B
Decreasing
Slightly volatile
Total Debt USD32 B33.1 B25.1 B
Increasing
Slightly volatile
Accounts Payable3.4 B4.1 BB
Increasing
Slightly volatile
Receivables8.9 BB7.5 B
Increasing
Slightly volatile
Inventories7.1 B7.3 B5.9 B
Increasing
Stable

Merck Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues43.7 B48.7 B43.4 B
Decreasing
Slightly volatile
Cost of Revenue13.4 B13.6 B14.8 B
Decreasing
Slightly volatile
Selling General and Administrative Expense9.6 B9.6 B10.9 B
Decreasing
Slightly volatile
Research and Development Expense11.9 B12.2 B9.5 B
Increasing
Slightly volatile
Operating Expenses24 B22.5 B21.5 B
Increasing
Very volatile
Income Tax Expense1.7 B1.5 B1.9 B
Increasing
Very volatile
Consolidated Income10.9 B13 B7.2 B
Increasing
Slightly volatile
Net Income to Non Controlling Interests(24.9 M)(24.3 M)33.1 M
Decreasing
Slightly volatile
Net Income10.9 B13 B7.1 B
Increasing
Slightly volatile
Net Income Common Stock10.9 B13 B7.1 B
Increasing
Slightly volatile
Weighted Average Shares2.5 B2.5 B2.8 B
Decreasing
Slightly volatile
Weighted Average Shares Diluted3.2 B2.9 B2.9 B
Decreasing
Slightly volatile
Earning Before Interest and Taxes EBIT12.8 B14.6 B9.1 B
Increasing
Slightly volatile
Revenues USD43.7 B48.7 B43.4 B
Decreasing
Slightly volatile
Net Income Common Stock USD10.9 B13 B7.1 B
Increasing
Slightly volatile
Earning Before Interest and Taxes USD12.8 B14.6 B9.1 B
Increasing
Slightly volatile
Gross Profit34.8 B35.1 B29 B
Increasing
Stable
Operating Income10.8 B12.5 B7.5 B
Increasing
Slightly volatile
Direct Expenses18.3 B17.8 B15.9 B
Decreasing
Stable

Merck Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals(13.2 B)(12.9 B)(2.9 B)
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals891.8 MB500 M
Increasing
Slightly volatile
Net Cash Flow from Financing2.8 B2.6 B(6.3 B)
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 1.5 B1.6 B1.1 B
Increasing
Stable
Net Cash Flow from Investing(17 B)(16.6 B)(4.8 B)
Decreasing
Slightly volatile
Net Cash Flow from Operations13.7 B14.1 B11.3 B
Increasing
Stable
Effect of Exchange Rate Changes on Cash (143.5 M)(133 M)(157 M)
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents15.1 M14 M(5.8 M)
Decreasing
Stable
Share Based Compensation453.4 M479 M357.5 M
Increasing
Slightly volatile
Depreciation Amortization and AccretionB3.2 B5.4 B
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.175.162.608
Increasing
Slightly volatile
Earnings per Diluted Share4.155.142.5864
Increasing
Slightly volatile
Earnings per Basic Share USD4.175.162.608
Increasing
Slightly volatile
Dividends per Basic Common Share2.532.641.9817
Increasing
Slightly volatile
Return on Average Equity0.310.3890.1887
Increasing
Slightly volatile
Return on Average Assets0.110.1370.0741
Increasing
Slightly volatile
Return on Invested Capital0.230.2590.1679
Increasing
Slightly volatile
Gross Margin0.760.720.665
Increasing
Slightly volatile
Profit Margin0.240.2680.1628
Increasing
Slightly volatile
EBITDA Margin0.330.3650.3298
Increasing
Very volatile
Return on Sales0.280.2990.2082
Increasing
Slightly volatile
Asset Turnover0.530.5120.4528
Increasing
Slightly volatile
Payout Ratio0.680.5120.9285
Decreasing
Very volatile
Enterprise Value over EBITDA14.0111.80913.0869
Increasing
Slightly volatile
Enterprise Value over EBIT20.7914.022.4453
Increasing
Stable
Price to Earnings Ratio15.2414.85327.6221
Increasing
Very volatile
Sales per Share19.1919.28215.906
Increasing
Slightly volatile
Price to Sales Ratio4.373.9753.8579
Increasing
Slightly volatile
Price to Book Value5.415.074.5909
Increasing
Slightly volatile
Debt to Equity Ratio1.811.7661.5035
Increasing
Slightly volatile
Dividend Yield0.03170.0340.0334
Decreasing
Slightly volatile
Current Ratio1.321.2681.5708
Decreasing
Slightly volatile
Free Cash Flow per Share3.813.8253.1858
Increasing
Very volatile
Book Value per Share14.0115.11714.6171
Decreasing
Slightly volatile
Tangible Assets Book Value per Share25.3624.34621.7647
Increasing
Slightly volatile
Total Assets Per Share41.9141.6335.6478
Increasing
Slightly volatile
Cash Flow Per Share3.523.653.7697
Increasing
Stable
Return on Investment11.5313.0111.301
Increasing
Slightly volatile
Operating Margin14.5314.8215.7774
Increasing
Slightly volatile
Calculated Tax Rate28.5422.3628.4264
Decreasing
Stable
Receivables Turnover5.695.896.1043
Decreasing
Stable
Inventory Turnover3.082.92.7239
Increasing
Stable
PPandE Turnover2.652.612.9682
Increasing
Very volatile
Cash and Equivalents Turnover4.554.864.7226
Increasing
Slightly volatile
Accounts Payable Turnover16.6213.2116.4147
Decreasing
Slightly volatile
Accrued Expenses Turnover36.7533.7633.1591
Decreasing
Slightly volatile
Interest Coverage10.949.2213.7758
Increasing
Very volatile
Long Term Debt to Equity0.970.90.6101
Increasing
Slightly volatile
Quick Ratio0.970.671.0286
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets0.560.559.198
Decreasing
Slightly volatile
Revenue to Assets0.440.470.4576
Increasing
Slightly volatile

Merck Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax12.8 B14.6 B9.1 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA15.4 B17.8 B14.4 B
Decreasing
Very volatile
Earnings Before Interest Taxes and Depreciation Amortization USD15.4 B17.8 B14.4 B
Decreasing
Very volatile
Market Capitalization198.8 B193.6 B165.8 B
Increasing
Slightly volatile
Enterprise Value216 B210 B179.9 B
Increasing
Slightly volatile
Invested Capital64.9 B62.6 B55.2 B
Increasing
Slightly volatile
Average Equity35 B33.6 B41.7 B
Decreasing
Slightly volatile
Average Assets90.9 B95.2 B97.1 B
Decreasing
Slightly volatile
Invested Capital Average52.9 B56.2 B54.4 B
Increasing
Stable
Tangible Asset Value57.5 B61.5 B59.5 B
Decreasing
Slightly volatile
Free Cash Flow8.7 B9.7 B8.7 B
Decreasing
Stable
Working Capital7.6 B6.4 B10.5 B
Decreasing
Slightly volatile
Revenue Per Employee553.8 K582.1 K584.6 K
Increasing
Slightly volatile
Net Income Per Employee78.3 K85.7 K79.2 K
Increasing
Slightly volatile

Merck Fundamental Market Drivers

Forward Price Earnings12.56
Short Percent Of Float0.84%
Average Daily Volume Last 10 Day11.82M
Shares Short Prior Month22.18M
Average Daily Volume In Three Month11.31M
Date Short Interest15th of December 2021
Fifty Day Average83.76
Two Hundred Day Average79.51

Merck Upcoming Events

Upcoming Quarterly Report3rd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End3rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Merck Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merck income statement, its balance sheet, and the statement of cash flows. Merck investors use historical funamental indicators, such as Merck's revenue or net income, to determine how well the company is positioned to perform in the future. Although Merck investors may use each financial statement separately, they are all related. The changes in Merck's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merck's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merck Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merck. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Cost of Revenue13.6 B13.4 B
Revenues48.7 B43.7 B
Revenue to Assets 0.47  0.44 
Revenue Per Employee582.1 K553.8 K
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 73000 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Merck without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Merck Correlation against competitors. Note that the Merck Company information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Merck Stock analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.